UC Irvine Health

Liver Cancer Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

LIVER CANCER

Symptom Management

UCI- 15-34** A Phase I study of Corydalis Yanhusuo to manage symptoms of peripheral chemotherapy-induced neuropathy (Seery)

EAY131 (MATCH) Molecular Analysis for Therapy Choice (Seery)

1st LINE Therapeutic

Unresectable

UCI 01-61 A Humanitarian device exemption use protocol of TheraSphere for treatment of Unresectable Hepatocellular Carcinoma (Imagawa)

UCI 15-80 Phase III Comparing Pexa-Vec Followed by Sorafenib vs. Sorafenib Pts w/ HCC w/o Prior Systemic Therapy (Abi-Jaoudeh)

UCI 15-81 Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma (Abi-Jaoudeh)

UCI 16-40 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (Imagawa)

Correlative

UCI 03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer (Imagawa)

UCI 16-29** Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization (Lam)

2nd LINE Therapeutic

Unresectable or Metastatic

UCI 16-81**
Comparing trans-arterial chemoembolization outcome using cone beam CT vs. conventional fluoroscopy (Abi-Jaoudeh)

UCI- 16-64 A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 IN Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations who Failed Previous Therapy (Seery)

v. 0417

**Opening soon

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu